09-03-2013, 06:59 PM
The effects of Shenfu Injection (SFI) on the heart have also been studied during those years. It seemed to have showed promising results on myocardial tissue and overall circulation.
One study, headed by Yang Wu published their paper around midyear of 2010. They investigated the traditional Chinese medicine (Shenfu) if it could attenuate an injury caused by diabetes which is known as myocardial ischemia-reperfusion (MI/R). They performed tests to several groups of diabetic rats including a group preconditioned with Shenfu injection. After the study, they found out that those which were preconditioned with the medicine, had a significantly lesser infarct size, apoptosis, caspase-3 protein expression, MDA level in myocardial tissues, and plasma level of CK and LDH but increased p-Akt, p-eNOS, bcl-2 protein expression, and SOD activity compared to the other groups. Their conclusion was that Shenfu Injection preconditioning actually protects hearts of diabetic patients from ischemia-reperfusion injury via P13K/Akt-dependent pathway.
Another study, performed by Song Wen-Ting and company, tried to use the Shenfu medication for heart failure. They published their research at the end of 2011. Though China has been using (SFI) for heart failure cases, the scientist’s purpose of the study was to determine how safe and effective the medication was.
Trials were conducted using local electronic databases and English ones. Patients with heart failure were placed into groups were some were on standard treatment and the other with routine treatment plus SFI. The results revealed that the latter showed better heart rate, walking distance, and even mortality results. Also, ultrasonic cardiography identified improved heart function of those with the combined SFI therapy. No serious adverse effects were reported. The study therefore was concluded that SFI appears to be an effective treatment for heart failure.
Another study conducted this year by Zhi-jun Guo and Chun-sheng Li had their research published as the Therapeutic Effects of Shenfu Injection on Post-cardiac Arrest Syndrome (PCAS). They have stated that for the past 50 years, cardiac arrest survival rates have not changed substantially which may be the reason why they delved in further with the topic. Their study comprises the discussion of how SFI can attenuate post-cardiac arrest myocardial dysfunction and cerebral injury. Also, they presented how SFI may be useful in PCAS treatment.
One study, headed by Yang Wu published their paper around midyear of 2010. They investigated the traditional Chinese medicine (Shenfu) if it could attenuate an injury caused by diabetes which is known as myocardial ischemia-reperfusion (MI/R). They performed tests to several groups of diabetic rats including a group preconditioned with Shenfu injection. After the study, they found out that those which were preconditioned with the medicine, had a significantly lesser infarct size, apoptosis, caspase-3 protein expression, MDA level in myocardial tissues, and plasma level of CK and LDH but increased p-Akt, p-eNOS, bcl-2 protein expression, and SOD activity compared to the other groups. Their conclusion was that Shenfu Injection preconditioning actually protects hearts of diabetic patients from ischemia-reperfusion injury via P13K/Akt-dependent pathway.
Another study, performed by Song Wen-Ting and company, tried to use the Shenfu medication for heart failure. They published their research at the end of 2011. Though China has been using (SFI) for heart failure cases, the scientist’s purpose of the study was to determine how safe and effective the medication was.
Trials were conducted using local electronic databases and English ones. Patients with heart failure were placed into groups were some were on standard treatment and the other with routine treatment plus SFI. The results revealed that the latter showed better heart rate, walking distance, and even mortality results. Also, ultrasonic cardiography identified improved heart function of those with the combined SFI therapy. No serious adverse effects were reported. The study therefore was concluded that SFI appears to be an effective treatment for heart failure.
Another study conducted this year by Zhi-jun Guo and Chun-sheng Li had their research published as the Therapeutic Effects of Shenfu Injection on Post-cardiac Arrest Syndrome (PCAS). They have stated that for the past 50 years, cardiac arrest survival rates have not changed substantially which may be the reason why they delved in further with the topic. Their study comprises the discussion of how SFI can attenuate post-cardiac arrest myocardial dysfunction and cerebral injury. Also, they presented how SFI may be useful in PCAS treatment.
![[+]](https://www.biotechnologyforums.com/images/netpen-pro/collapse_collapsed.png)